These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16698321)

  • 1. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
    Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME
    Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
    Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
    Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunology of neonatal gene transfer.
    Ponder KP
    Curr Gene Ther; 2007 Oct; 7(5):403-10. PubMed ID: 17979686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroviral vector design studies toward hematopoietic stem cell gene therapy for mucopolysaccharidosis type I.
    Pan D; Aronovich E; McIvor RS; Whitley CB
    Gene Ther; 2000 Nov; 7(21):1875-83. PubMed ID: 11110421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
    Metcalf JA; Ma X; Linders B; Wu S; Schambach A; Ohlemiller KK; Kovacs A; Bigg M; He L; Tollefsen DM; Ponder KP
    Mol Ther; 2010 Feb; 18(2):334-42. PubMed ID: 19844196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.
    Meertens L; Zhao Y; Rosic-Kablar S; Li L; Chan K; Dobson H; Gartley C; Lutzko C; Hopwood J; Kohn D; Kruth S; Hough MR; Dubé ID
    Hum Gene Ther; 2002 Oct; 13(15):1809-20. PubMed ID: 12396614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
    Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
    Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.
    Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E
    Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.